Foghorn Therapeutics Inc. (FHTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 17, 2025, discloses the results of Foghorn Therapeutics Inc.'s 2025 Annual Meeting of Stockholders. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Cambridge, MA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders approved all matters submitted at the Annual Meeting. Key voting statistics include:
- Shares Entitled to Vote: 55,721,340
- Shares Present or Represented: 43,369,822
- Proposal 1: Election of Class II Directors
- All four nominees (Stuart Duty, Neil J. Gallagher, Adrian Gottschalk, Ian F. Smith) were elected.
- Notable Vote Split: Ian F. Smith received the highest number of "Against" votes (3,754,839) and Adrian Gottschalk received 1,132,490 "Against" votes, while Stuart Duty and Neil J. Gallagher received significantly fewer dissenting votes.
- Broker Non-Votes: 8,679,708
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of Deloitte & Touche LLP for the fiscal year ending December 31, 2025.
- Votes For: 43,340,301
- Votes Against: 16,978
- Abstentions: 12,543
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of the voting results.
Investor Verification Checklist
- Review the Proxy Statement filed on May 5, 2025, for detailed biographies of the elected directors and the rationale behind the significant "Against" votes for Ian F. Smith and Adrian Gottschalk.
- Verify the Company's cash position and burn rate in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Confirm the tenure and specific responsibilities of the newly elected Class II directors.